Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPIIb/llla Inhibitors in Animal Models of Platelet-Mediated Thrombosis

Summary

Cyclic Arg-Gly-Asp (RGD) containing synthetic peptides such as L-cysteine, N-(mercaptoacetyl)-D-tyrosyl-L-arginylglycyl-L-a-aspartyl-cyclic (1→5)-sulfide, 5-oxide (G4120) and acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginyl-glycyl-L-α-aspartyl-[0-methyltyrosyl]-L-arginyl-L-cysteinamide, cyclic 1→9-sulfide (TP9201) bind with high affinity to the platelet GPIIb/IIIa receptor.

The relationship between antithrombotic effect, ex vivo platelet aggregation and bleeding time prolongation with both agents was studied in hamsters with a standardized femoral vein endothelial cell injury predisposing to platelet-rich mural thrombosis, and in dogs with a carotid arterial eversion graft inserted in the femoral artery. Intravenous administration of G4120 in hamsters inhibited in vivo thrombus formation with a 50% inhibitory bolus dose (ID₅₀) of approximately 20 μg/kg, ex vivo ADP-induccd platelet aggregation with ID50 of 10 μg/kg, and bolus injection of 1 mg/kg prolonged the bleeding time from 38 ± 9 to 1,100 ± 330 s. Administration of TP9201 in hamsters inhibited in vivo thrombus formation with ID₅₀ of 30 μg/kg, ex vivo platelet aggregation with an ID₅₀ of 50 μg/kg and bolus injection of 1 mg/kg did not prolong the template bleeding time. In the dog eversion graft model, infusion of 100 μg/kg of G4120 over 60 min did not fully inhibit platelet-mediated thrombotic occlusion but was associated with inhibition of ADP-induccd ex vivo platelet aggregation and with prolongation of the template bleeding time from 1.3 ± 0.4 to 12 ± 2 min. Infusion of 300 μg/kg of TP9201 over 60 min completely prevented thrombotic occlusion, inhibited ex vivo platelet aggregation, but was not associated with prolongation of the template bleeding time.

TP9201, unlike G4120, inhibits in vivo platelet-mediated thrombus formation without associated prolongation of the template bleeding time.

• References

• 1 Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966; 48: 19-44
• 2 Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73
• 3 Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986; 315: 1023-5
• 4 Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986; 8: 245-50
• 5 Collen D, Gold HK. Fibrin-specific thrombolytic agents and new approaches to coronary arterial thrombolysis. In: Julian D, Kiibler W, Norris RM, Swan HJ C, Collen D, Vcrstractc M. (eds) Thrombolysis in Cardiovascular Diseases. New York: Marcel Dekker Inc; 1989: 45-67
• 6 Folts JD, Crowell Jr EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70
• 7 Sharma B, Wyeth RP, Heincmann FA, Kolath G. Adjunctive use of intracoronary prostaglandin E₁ with streptokinase enhances coronary thrombolysis. Circulation 1987; 76: IV-181 (abstract)
• 8 Aiken JW, Shcbuski RJ, Miller OV, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 1981; 219: 299-308
• 9 Imura Y, Tcrashita Z, Nishikawa K. The role of thromboxane (TX) A₂ in rabbit arterial thrombosis induced by endothelial damage. Thromb Res 1990; 59: 195-205
• 10 Golino P, Ashton JH, Mc Natt J, Glas-Grecnwalt P, Sheng-Kun Y, O’Brien RA, Buja LM, Willerson JT. Simultaneous administration of thromboxane A₂- and serotonin S₂-reccptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation 1989; 79: 911-9
• 11 Dc Clerck F, Xhonncux B, Van Gorp L, Bcetcns J, Janssen PA J. S₂-scrotoncrgic receptor inhibition (ketanserin), combined with thromboxane A₂/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect. Thromb Haemost 1986; 56: 236 (letter)
• 12 Dc Clerek F, Beetens J, Van de Water A, Vercammen E, Janssen PA J. R68070: Thromboxane A₂ synthetase inhibition and thromboxane A₂/prostaglandin endoperoxide receptor blockade combined in one molecule – II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989; 61: 43-9
• 13 Hoet B, Falcon C, De Reys C, Arnout J, Deckmyn H, Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitors, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 1990; 75: 646-53
• 14 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-8
• 15 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65
• 16 Fitzgerald DJ, Fitz Gerald GA. Role of thrombin and thromboxane A ₂in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989; 86: 7585-9
• 17 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibiton. Circulation 1990; 81: 219-25
• 18 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-63
• 19 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-56
• 20 Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab’)₂ fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985; 66: 1456-9
• 21 Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry 1989; 28: 661-6
• 22 Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper. Echis carinatus. J Biol Chem 1988; 263: 19827-32
• 23 Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein GPIIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471-5
• 24 Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-61
• 25 Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517-8
• 26 Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 1987; 262: 17294-8
• 27 Nichols A, Vasko J, Koster P, Smith J, Barone F, Nelson A, Stadel J, Powers D, Rhodes G, Miller-Stein C, Boppana V, Bennet D, Berry D, Romoff T, Calvo R, Ali F, Sorenson E, Samanen J. SK&F 106760, a novel GPIIb/IIIa antagonist: antithrombotic activity and potentiation of streptokinase-mediated thrombolysis. Eur J Pharmacol 1990; 183: 2019 (abstract)
• 28 Feigen LP, Nicholson NS, Taite BB, Panzer-Knodle SG, King LW, Salyers AK, Gorczynski RJ, Adams SP. Inhibition of the platelet glycoprotein IIb/IIIa receptor by an analog to RGDS. FASEB 1989; 3: 309A
• 29 Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS, Deisher T, Eigenbrot C, Gadek TR, Gantzos R, Lifari MT. et al Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992; 35: 2040-8
• 30 Bunting S, Kaplan AV, Leung LK, Fischell TA, Leung WH, Grant GW, Bullens S, Hasko J, Lipari M, Muir C, Pitti R, Napier MA. The synthetic cyclic peptide G1120 reversibly inhibits GPIIb/IIIa and reduces platelet deposition at the site of balloon angioplasty. Arterioscl Thromb 1991; 11: 1587a (abstract)
• 31 Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glyeoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-6
• 32 Gold HK, Coller BS, Yasuda T, Saitro T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collcn D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/ Ilia antibody in a canine preparation. Circulation 1988; 77: 670-7
• 33 Shebuski RJ, Berry DE, Bennett DB, Romoff T, Storer BL, Ali F, Samanen J. Demonstration of Ac-Arg-Gly-Asp-Ser-NH₂ as an antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost 1989; 61: 183-8
• 34 Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine reparation. Circulation 1991; 83: 1038-47
• 35 Imura Y, Stassen JM, Bunting S, Stockmans F, Collen D. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood 1992; 80: 1247-53
• 36 Yasuda T, Gold HK, Kohmura C, Guerrero L, Yaoita H, Fallon JT, Bunting S, Collen D. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustaines coronary arterial thrombolysis with rt PA in a canine preparation. Arterioscl Thromb 1993; 13: 738-47
• 37 Lu HR, Gold HK, Wu Z, Yasuda T, Pauwels P, Rapold HJ, Napier M, Bunting S, Collen D. G4120, an Arg-Gly-Asp containing pentapeptide enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemost 1992; 67: 686-91
• 38 Tschopp JF, Bell DJ, Bunting S. et al Novel RGD-based glycoprotein IIb/IIIa receptor antagonists as antithrombotics. Blood 1992; 80 Suppl (Suppl. 01) 320a (abstract)
• 39 Born QV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927
• 40 Stockmans F, Deckmyn H, Gruwez J, Yermylen J, Acland R. Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65: 425-31
• 41 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84
• 42 Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, Inc; 1973
• 43 Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-20
• 44 Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation 1988; 78: 546-56
• 45 Theroux P, Quimel H, Mc Cans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, de Guise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11
• 46 Scarborough RM, Hus MA, Teng W, Rose JW, Nannizzi L, Campbell AM, Charo IF. Potent and integrin specific KGD-containing platelet antagonists designed from the GPIIb-IIIa specific antagonist bar-bourin. Thromb Haemost 1991; 65: 843 (abstract)
• 47 Hauson SR, Kolzé HF, Harkei LA, Scarborough RM, Clrato IF, Phillips DR. Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein (GP) IIb/IIIa. Thromb Haemost 1991; 65: 813 (abstract)